The results of a recent study that was published in the journal of Circulation, suggest that low-density lipoprotein ...

Elevated Remnant Cholesterol tied to increased ASCVD events in Individuals With Diabetes suggests a study published in the ...

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more ...

While statins can reduce LDL levels and ASCVD events, high Lp(a) poses an independent risk that will need attention, too.

One is an siRNA biologic, the other an oral agent, but both lowered Lp(a) levels by 80% or more in ASCVD patients.

Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns ...

Altered sphingolipid biosynthetic flux and lipoprotein trafficking contribute to trans fat-induced atherosclerosis - (https:/ ...

A study was conducted to determine the association between housing unaffordability and health outcomes and medication ...

On Monday, Silence Therapeutics plc (NASDAQ:SLN) presented end-of-treatment data from its Phase 2 ALPACAR-360 study of ...

With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an ...

Silence Therapeutics (SLN) presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA, or siRNA, ...

The recently launched National Action Plan on Obesity, Diabetes, and Modifiable Risk Factors for Atherosclerotic ...